GlassScriptPhysician profile
Shawna E Dellay
NPI 1710386214
$2,179.30
in general payments reported to CMS, 2019-2025
30 companies · $976 in 2025
The $976 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $269 · 2023: $325 · 2024: $609 · 2025: $976.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,911.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,910.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $592.57 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $320.07 | 2023-2025 | Caplyta |
| Alkermes, INC. | $183.18 | 2023-2025 | Aristada, Lybalvi |
| Pfizer INC. | $140.11 | 2024-2025 | |
| Axsome Therapeutics, INC. | $93.93 | 2024-2025 | Auvelity |
| Lundbeck LLC | $80.94 | 2022-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $77.02 | 2023-2025 | Rexulti, Nuedexta |
| Vanda Pharmaceuticals INC. | $76.35 | 2022-2025 | Fanapt, Hetlioz |
| Tris Pharma INC | $51.07 | 2024-2025 | Dyanavel Xr |
| Novo Nordisk INC | $48.05 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $37.93 | 2022 | |
| Almatica Pharma LLC | $36.99 | 2024 | Loreev Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.80 | 2024-2025 | Relistor, Xifaxan |
| Paratek Pharmaceuticals, INC. | $34.25 | 2022-2025 | Nuzyra |
| Exact Sciences Corporation | $34.11 | 2023 | Cologuard Collection Kit |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $32.85 | 2024 | Uzedy |
| Corium, LLC | $31.02 | 2022-2025 | Azstarys |
| Idorsia Pharmaceuticals US INC | $30.29 | 2022-2023 | Quviviq |
| Neuronetics, INC. | $30.10 | 2022 | |
| Orexo US, INC. | $28.37 | 2023 | Zubsolv |
| Merck Sharp & Dohme LLC | $27.94 | 2023-2024 | Verquvo, Belsomra, Gardasil |
| Indivior INC. | $24.85 | 2025 | Sublocade |
| Hologic Sales and Service, LLC | $20.32 | 2022 | |
| Gilead Sciences, INC. | $20.30 | 2025 | |
| Glaxosmithkline, LLC. | $18.05 | 2025 | Arexvy, Shingrix |
| Neurocrine Biosciences, INC. | $16.09 | 2024 | Ingrezza |
| Amgen INC. | $14.32 | 2025 | Repatha, Otezla |
| Organon LLC | $14.20 | 2022 | |
| Lilly USA, LLC | $13.73 | 2025 | Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $13.50 | 2025 | Breztri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shawna Dellay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.